Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,627 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,360 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03412383 | Pyrotinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer | unknown | Phase 2 | 14 | Peking Union Medical CollegeOTHER | 1 | Jan 30, 2018 | clinicaltrials |
| NCT02910050 | Bicalutamide Plus Aromatase Inhibitors in ER(+)/AR(+)/HER2(-) Metastatic Breast Cancer(BETTER) | unknown | Phase 2 | 58 | Xu feiOTHER | 1 | Dec 22, 2017 | clinicaltrials |
| NCT03373708 |
| Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast Cancer |
| unknown |
| Phase 2 / Phase 3 |
| 200 |
| Zhiyong YuOTHER |
| 0 |
| Dec 18, 2017 |
| clinicaltrials |
| NCT03348098 | Clinical Study of Neoadjuvant Therapy With Apatinib and Paclitaxel in Local Advanced Triple-negative Breast Cancer | unknown | Phase 2 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Nov 28, 2017 | clinicaltrials |
| NCT03349177 | Pathological Complete Response Rate in Locally Advanced Breast Cancer With FEC, EC-T, or TC as Neoadjuvant Chemotherapy | unknown | Phase 2 / Phase 3 | 200 | Zhiyong YuOTHER | 0 | Nov 21, 2017 | clinicaltrials |
| NCT02694224 | Addition of Vismodegib to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer Patients(SHH-CM) | unknown | Phase 2 | 40 | Clinica Universidad de Navarra, Universidad de NavarraOTHER | 1 | Oct 24, 2017 | clinicaltrials |
| NCT02673268 | Robot Assisted Mastectomy Via Axillary Way With Areola Conservation and Immediate Reconstruction(MARCI) | unknown | Phase 2 | 80 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Oct 12, 2017 | clinicaltrials |
| NCT00723294 | Cryoablation Therapy in Treating Patients With Invasive Ductal Breast Cancer | unknown | Phase 2 | 99 | Alliance for Clinical Trials in OncologyOTHER | 1 | Aug 14, 2017 | clinicaltrials |
| NCT03085368 | A Randomized Controlled Trial of HER-2 Positive Breast Cancer Patients Treated With Lapatinib vs Herceptin | unknown | Phase 2 / Phase 3 | 482 | Peking Union Medical College HospitalOTHER | 1 | Jul 28, 2017 | clinicaltrials |
| NCT03213925 | Neoadjuvant Chemotherapy Followed by Radiotherapy Alone in Patients With Breast Cancer | unknown | Phase 2 | 1 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Jul 11, 2017 | clinicaltrials |
| NCT03211572 | The EMPOwER Study Evaluating Multiparameter Gene Testing as a Predictor of Short Term Endocrine Therapy Response in Hormone Receptor Positive Breast Cancers(OTT 17-01) | unknown | Phase 2 | 82 | Ottawa Hospital Research InstituteOTHER | 0 | Jul 7, 2017 | clinicaltrials |
| NCT01830244 | IST Neoadjuvant Abraxane in Newly Diagnosed Breast Cancer(Neonab) | unknown | Phase 2 | 60 | Barwon HealthOTHER_GOV | 1 | Jul 2, 2017 | clinicaltrials |
| NCT03204734 | Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen at Least 2nd Line in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer | unknown | Phase 2 | 132 | Zhejiang Cancer HospitalOTHER | 1 | Jul 2, 2017 | clinicaltrials |
| NCT02684318 | Study to Evaluate PM01183 in Combination With Olaparib in Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 100 | Poveda, Andrés, M.D.INDIV | 1 | Jun 22, 2017 | clinicaltrials |
| NCT03192293 | Metformin and Simvastatin in Addition to Fulvestrant | unknown | Phase 2 | 28 | National University Hospital, SingaporeOTHER | 1 | Jun 20, 2017 | clinicaltrials |
| NCT03168074 | Phase II Study of Single Agent Lenvatinib | unknown | Phase 2 | 30 | National University Hospital, SingaporeOTHER | 1 | Jun 16, 2017 | clinicaltrials |
| NCT03147963 | Docetaxel 2-weeks Regimen in the Treatment of HER2 Negative Metastatic Breast Cancer | unknown | Phase 2 | 90 | Zhejiang Cancer HospitalOTHER | 1 | May 10, 2017 | clinicaltrials |
| NCT02617043 | Hypofractionated Whole-breast Irradiation With Simultaneously Integrated Boost For Early-Stage Breast Cancer After Breast-conserving Surgery(HF-WBI-SIB) | unknown | Phase 2 | 200 | Fudan UniversityOTHER | 1 | May 2, 2017 | clinicaltrials |
| NCT01266213 | Fulvestrant (F)/Goserelin (G) vs Anastrozole (A)/G vs G for Premenopausal Women(FLAG) | unknown | Phase 2 | 147 | Samsung Medical CenterOTHER | 1 | May 1, 2017 | clinicaltrials |
| NCT02144194 | Maintenance Oral Vinorelbine or Observation After Vinorelbine-Docetaxel First Line Chemotherapy in Advanced Breast Ca(TNM) | unknown | Phase 2 | 65 | Cancer Research Group - Collaborative Group, Beirut, Lebanon.OTHER | 1 | Feb 9, 2017 | clinicaltrials |
| NCT01283789 | Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer | unknown | Phase 2 | 23 | University of Kansas Medical CenterOTHER | 1 | Feb 8, 2017 | clinicaltrials |
| NCT02396108 | Dose-confirmation Study of ASLAN001 Combined With Weekly Paclitaxel and Carboplatin in Advanced Solid Tumours, Followed by a Study in Patients With Stage I-III HER2 Positive Breast Cancer | unknown | Phase 1 / Phase 2 | 55 | National University Hospital, SingaporeOTHER | 1 | Feb 3, 2017 | clinicaltrials |
| NCT00491816 | Erlotinib Plus Chemotherapy for Treatment of Triple Negative Breast Cancer | unknown | Phase 2 | 32 | University of Kansas Medical CenterOTHER | 1 | Jan 19, 2017 | clinicaltrials |
| NCT02052102 | Study to See Whether Breath-Hold Techniques During RT Are Effective in Helping to Improve Sparing of the Heart | unknown | Phase 2 | 63 | AHS Cancer Control AlbertaOTHER | 1 | Jan 6, 2017 | clinicaltrials |
| NCT02646735 | Fulvestrant 500mg With Exemestane Endocrine Therapy for Postmenopausal Advanced Breast Cancer Patients(FRIEND) | unknown | Phase 2 | 148 | Chinese Academy of Medical SciencesOTHER | 1 | Jan 2, 2017 | clinicaltrials |
| NCT02333890 | A Phase 2 Randomized, Double-blind Trial Evaluating the Effects of Chloroquine in Breast Cancer(CUBiC) | unknown | Phase 2 | 60 | Ottawa Hospital Research InstituteOTHER | 1 | Nov 18, 2016 | clinicaltrials |
| NCT00499603 | Paclitaxel Followed by FEC Versus Paclitaxel and RAD001 Followed by FEC In Women With Breast Cancer | unknown | Phase 2 | 62 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 1, 2016 | clinicaltrials |
| NCT02934828 | Study of Preoperative Chemotherapy for Early Triple Negative or HER2-positive Operable Breast Cancer | unknown | Phase 2 | 230 | Chinese Academy of Medical SciencesOTHER | 1 | Oct 18, 2016 | clinicaltrials |
| NCT00957125 | A Translational Trial on Molecular Markers and Functional Imaging to Predict Response of Preoperative Treatment of Breast Cancer Early(PROMIX) | unknown | Phase 2 | 151 | Thomas HatschekOTHER | 1 | Sep 8, 2016 | clinicaltrials |
| NCT02886897 | A Study of Combinations of D-CIK Immunotherapy And Anti-PD-1 In Refractory Solid Tumors | unknown | Phase 1 / Phase 2 | 50 | Sun Yat-sen UniversityOTHER | 1 | Sep 1, 2016 | clinicaltrials |
| NCT02842099 | Standard Chemotherapy Followed by Capecitabine as Prolonged Postoperative Adjuvant Treatment for Breast Cancer | unknown | Phase 2 | 500 | Peking Union Medical College HospitalOTHER | 1 | Jul 22, 2016 | clinicaltrials |
| NCT02838238 | X Versus Placebo as Postoperative Adjuvant Treatment for Elder Breast Cancer | unknown | Phase 2 | 300 | Peking Union Medical College HospitalOTHER | 1 | Jul 20, 2016 | clinicaltrials |
| NCT02829008 | Low -Dose-bevacizumab and Pemetrexed Versus TPC in Metastatic HER2-negative Breast Cancer Patients | unknown | Phase 2 | 120 | Chinese Academy of Medical SciencesOTHER | 1 | Jul 12, 2016 | clinicaltrials |
| NCT02817334 | A Prospective Clinical Study for Evaluation of Safe Resection Margin in Breast Conserving Surgery in Breast Cancer | unknown | Phase 2 | 149 | National Cancer Center, KoreaOTHER_GOV | 1 | Jun 29, 2016 | clinicaltrials |
| NCT01176799 | Randomized Study of Doxorubicin and Cyclophosphamide With or Without Intermittent Sunitinib in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer Patients With Measurable Primary Breast Tumor | unknown | Phase 2 | 73 | National University Hospital, SingaporeOTHER | 1 | Jun 22, 2016 | clinicaltrials |
| NCT01803503 | Docetaxel With or Without Low-dose, Short Course Sunitinib in Refractory Solid Tumors | unknown | Phase 2 | 80 | National University Hospital, SingaporeOTHER | 1 | Jun 22, 2016 | clinicaltrials |
| NCT02030561 | NK Cell Infusions With Trastuzumab for Patients With HER2+ Breast and Gastric Cancer | unknown | Phase 1 / Phase 2 | 29 | National University Hospital, SingaporeOTHER | 1 | Jun 22, 2016 | clinicaltrials |
| NCT02175446 | Safety and Efficacy Study of Eribulin in Combination With Bevacizumab for Second-line Treatment HER2- MBC Patients(GIM11-BERGI) | unknown | Phase 2 | 61 | Consorzio OncotechOTHER | 1 | Jun 15, 2016 | clinicaltrials |
| NCT02238509 | Safety and QoL of Trastuzumab With Lapatinib or Chemiotherapy in MBC and HER2+ Patients Refractory to Anti HER2 Therapies | unknown | Phase 2 | 154 | Consorzio OncotechOTHER | 1 | Jun 15, 2016 | clinicaltrials |
| NCT02790580 | Dose-dense Doxorubicin/Cyclophosphamide With Intermittent Low-dose Sunitinib in Breast Cancer Patients | unknown | Phase 2 | 98 | National University Hospital, SingaporeOTHER | 1 | Jun 6, 2016 | clinicaltrials |
| NCT02511847 | Trial of Afatinib With Paclitaxel for Neoadjuvant Therapy of TNBC and Research of Biomarkers of Afatinib | unknown | Phase 2 | 40 | National Taiwan University HospitalOTHER | 1 | Apr 15, 2016 | clinicaltrials |
| NCT02685657 | Neoadjuvant Chemotherapy Docetaxel With or Without SELUMETINIB in Patients With Triple Negative Breast Cancer | unknown | Phase 2 | 164 | Russian Academy of Medical SciencesOTHER | 0 | Feb 22, 2016 | clinicaltrials |
| NCT02681562 | Olaparib in Locally Advanced ER, PgR and HER2 Negative (Triple Negative) and in Locally Advanced Germline BRCA Mutation-positive Breast Cancer Patients | unknown | Phase 2 | 45 | Istituti Ospitalieri di CremonaOTHER | 0 | Feb 15, 2016 | clinicaltrials |
| NCT01784120 | A Phase II Trial of Doxorubicin and Genexol-PM in Patients With Advanced Breast Cancer | unknown | Phase 2 | 48 | Gachon University Gil Medical CenterOTHER | 1 | Feb 10, 2016 | clinicaltrials |
| NCT01016886 | Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research(MANTICORE) | unknown | Phase 1 / Phase 2 | 99 | University of AlbertaOTHER | 1 | Feb 9, 2016 | clinicaltrials |
| NCT02649101 | Thalidomide Plus Chemotherapy Versus Chemotherapy Alone for Advanced Breast Cancer | unknown | Phase 2 | 60 | Zhejiang Cancer HospitalOTHER | 1 | Jan 7, 2016 | clinicaltrials |
| NCT02230319 | Prevention of Paclitaxel Neuropathy With Cryotherapy | unknown | Phase 2 | 39 | Medical Oncology & Hematology Associates of Northern VirginiaOTHER | 1 | Oct 1, 2015 | clinicaltrials |
| NCT02544243 | Vinorelbine/Gemcitabine Versus Vinorelbine/Cisplatin in Metastatic Breast Cancer | unknown | Phase 2 | 200 | Shandong Cancer Hospital and InstituteOTHER | 0 | Sep 9, 2015 | clinicaltrials |
| NCT02294565 | VST-1001 (Dilute Fluorescein) for Lymphatic Mapping & Localization of Lymph Nodes in Patients With Breast Cancer | unknown | Phase 1 / Phase 2 | 147 | Vestan, Inc.INDUSTRY | 1 | Jul 27, 2015 | clinicaltrials |
| NCT02473159 | Clinical Application of Near-infrared Fluorescence Guided Localization on Breast Surgery in Breast Cancer | unknown | Phase 2 | 5 | National Cancer Center, KoreaOTHER_GOV | 1 | Jun 18, 2015 | clinicaltrials |
Data updated 23 days agoSource updated Jan 30, 2018source: clinicaltrials